PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE Drug Patent Profile
Which patents cover Pantoprazole Sodium In 0.9% Sodium Chloride, and what generic alternatives are available?
Pantoprazole Sodium In 0.9% Sodium Chloride is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.
The generic ingredient in PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE is pantoprazole sodium. There is one drug master file entry for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the pantoprazole sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pantoprazole Sodium In 0.9% Sodium Chloride
A generic version of PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE was approved as pantoprazole sodium by APOTEX on January 19th, 2011.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE?
- What are the global sales for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE?
- What is Average Wholesale Price for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE?
Summary for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 23 |
| DailyMed Link: | PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE at DailyMed |
Recent Clinical Trials for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Alexandria University | Phase 3 |
| Mansoura University | Phase 1/Phase 2 |
| Federal University of São Paulo | Phase 4 |
See all PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE clinical trials
Pharmacology for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
| Drug Class | Proton Pump Inhibitor |
| Mechanism of Action | Proton Pump Inhibitors |
US Patents and Regulatory Information for PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE | pantoprazole sodium | SOLUTION;INTRAVENOUS | 217512-001 | Feb 14, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Baxter Hlthcare Corp | PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE | pantoprazole sodium | SOLUTION;INTRAVENOUS | 217512-002 | Feb 14, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Baxter Hlthcare Corp | PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE | pantoprazole sodium | SOLUTION;INTRAVENOUS | 217512-003 | Feb 14, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Pantoprazole Sodium in 0.9% Sodium Chloride: Market Dynamics, Patent Exposure, and Financial Trajectory
Pantoprazole sodium in 0.9% sodium chloride is a mature, genericized intravenous proton-pump inhibitor product used mainly in hospitals. Its commercial outlook is driven by hospital purchasing contracts, supply reliability, manufacturing cost, and the shift from injectable to oral therapy rather than by patent exclusivity.
Standalone revenue for pantoprazole sodium in 0.9% sodium chloride is generally not disclosed by manufacturers. The product is usually reported within broader generic injectable, hospital products, or gastrointestinal portfolios. The financial profile is therefore best assessed through market structure, regulatory status, pricing pressure, utilization, and supplier economics.
What is pantoprazole sodium in 0.9% sodium chloride?
Pantoprazole sodium in 0.9% sodium chloride is a ready-to-use intravenous formulation of pantoprazole, typically supplied as a 40 mg dose in a 100 mL sodium chloride bag. It is administered by intravenous infusion when oral therapy is not appropriate.
The product is an injectable proton-pump inhibitor that suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase enzyme. The principal hospital uses are short-term treatment of gastroesophageal reflux disease when oral therapy is unavailable and reduction of acid secretion in selected inpatient settings.
| Product characteristic | Commercial profile |
|---|---|
| Active ingredient | Pantoprazole sodium |
| Dosage form | Intravenous infusion |
| Common presentation | 40 mg in 100 mL of 0.9% sodium chloride |
| Therapeutic class | Proton-pump inhibitor |
| Primary customers | Hospitals, health systems, group purchasing organizations |
| Regulatory pathway | NDA for the originator; ANDA or other abbreviated pathway for generic products |
| Patent status | Core product patents expired |
| Current market structure | Multiple generic and hospital-injectable suppliers |
| Revenue disclosure | Usually not reported separately |
The premixed bag competes with pantoprazole vials that require reconstitution and dilution before administration. The bag can reduce pharmacy preparation time and handling requirements, but it typically carries higher packaging, fill-finish, and logistics costs.
What is the FDA regulatory status of pantoprazole sodium injection?
The original intravenous pantoprazole product, Protonix I.V., was approved by the FDA as a prescription injection. Current U.S. products include generic pantoprazole sodium for injection and premixed pantoprazole sodium in 0.9% sodium chloride injection products listed in FDA and DailyMed databases. Product-specific strength, container, storage, and labeling details vary by manufacturer.[1][2]
Pantoprazole injection is not a biologic. Biosimilar regulation therefore does not apply. Competition occurs through generic drug pathways, primarily abbreviated new drug applications for products that meet applicable pharmaceutical equivalence and bioequivalence requirements.
Is pantoprazole sodium in 0.9% sodium chloride an ANDA product?
Most generic versions are expected to rely on abbreviated approval pathways, while the original branded product was approved under a full NDA. Ready-to-use premixed presentations may require additional manufacturing and stability data because the container, dilution medium, infusion configuration, and storage characteristics are part of the finished product.
The practical regulatory barriers are lower than for a new chemical entity but higher than for a simple oral solid. Injectable products must demonstrate control of sterility, particulate matter, container closure integrity, extractables and leachables, stability, and aseptic or terminal sterilization processes, depending on the product design.
When does pantoprazole lose exclusivity?
Pantoprazole has already lost core market exclusivity in the United States. The original compound and early formulation protection expired years ago, allowing generic oral and injectable competition.
| Exclusivity category | Status |
|---|---|
| New chemical entity exclusivity | Expired |
| Core compound patent protection | Expired |
| Original Protonix commercial exclusivity | Expired |
| Generic oral competition | Established |
| Generic injectable competition | Established |
| Premixed sodium chloride presentation | Subject to product-specific regulatory and manufacturing barriers, not meaningful core-molecule exclusivity |
The expiration of the main pantoprazole patent estate means commercial protection depends on execution rather than exclusivity. Suppliers compete on price, contract access, fill rates, shortage performance, and the ability to maintain FDA-compliant sterile manufacturing.
What patents protect pantoprazole sodium in 0.9% sodium chloride?
No active, commercially meaningful patent barrier is generally expected to protect the pantoprazole molecule itself in the U.S. The relevant residual rights, if any, would be product-specific and could involve container systems, formulation parameters, manufacturing processes, or particular methods of use.
The original Protonix patent portfolio included patents associated with pantoprazole and its pharmaceutical formulations. Those rights are now expired or commercially exhausted for the core injectable market. Current generic entry is therefore unlikely to be blocked by the historical branded patent estate.
Are formulation patents a meaningful risk?
Formulation patents can matter in injectable products, but their value is narrower than a compound patent. A formulation patent may cover a particular concentration, pH range, stabilizer system, container, lyophilized form, or ready-to-use presentation. Its commercial effect depends on whether competing manufacturers can design around the claims while maintaining an acceptable product profile.
For pantoprazole sodium in 0.9% sodium chloride, the main technical barriers are likely to be:
- Chemical and physical stability in the infusion bag
- Prevention of precipitation or degradation
- Container compatibility
- Sterility assurance
- Low particulate levels
- Shelf-life validation
- Cold-chain or controlled-storage requirements, if applicable
- Scalable aseptic filling
These barriers can delay entry or reduce the number of reliable suppliers without creating durable monopoly pricing.
Are method-of-use patents relevant?
Method-of-use patents are unlikely to create significant market protection for the broad inpatient use of intravenous pantoprazole. The main indications are established, and generic labels generally cover the clinically relevant uses after applicable regulatory approval.
A narrow method-of-use claim could affect a specific dosing protocol or patient population, but hospital purchasing decisions usually focus on the overall labeled product and formulary utility. The commercial impact of a narrow method-of-use patent would therefore be limited unless the patented use represented a substantial share of utilization.
How many companies compete in the pantoprazole injection market?
The U.S. market has multiple generic injectable suppliers, although the number of dependable suppliers for a specific premixed bag presentation may be smaller than the number of suppliers listed in a broad product category.
Competition can include:
- Large generic injectable manufacturers
- Hospital-product companies
- Contract manufacturers
- Specialty injectable suppliers
- Suppliers of vials that compete with ready-to-use bags
- Distributors and repackagers operating within applicable regulatory limits
The relevant competitive unit is not simply the number of approved products. Hospitals typically evaluate whether a supplier can provide continuous inventory, meet purchasing-contract terms, support recalls, and maintain supply during manufacturing interruptions.
What is the competitive landscape for pantoprazole sodium versus other acid-suppression drugs?
Pantoprazole injection competes with other intravenous proton-pump inhibitors and with non-PPI acid-suppression products. It also competes indirectly with oral and enteral formulations because many patients can transition rapidly from intravenous to oral therapy.
| Competitor | Competitive position |
|---|---|
| Pantoprazole injection vial | Lower manufacturing complexity than a premixed bag; requires pharmacy preparation |
| Pantoprazole premixed bag | Operational convenience; higher packaging and manufacturing cost |
| Omeprazole injection | Alternative intravenous PPI in some markets |
| Esomeprazole injection | Branded or generic alternative with different pricing and formulary positioning |
| Famotidine injection | H2-receptor antagonist alternative |
| Oral pantoprazole | Lower-cost step-down option when oral administration is feasible |
| Other oral PPIs | Major indirect competitors because they reduce duration of IV treatment |
The strongest commercial pressure comes from therapeutic substitution and IV-to-oral conversion. Hospitals may purchase the product for clinical convenience, but they have an incentive to minimize injectable treatment duration.
What drives demand for pantoprazole sodium in 0.9% sodium chloride?
Demand is relatively stable but not structurally high-growth. Key drivers include:
- Inpatient admissions requiring temporary acid suppression.
- Patients who cannot swallow or absorb oral medication.
- Perioperative and intensive-care protocols.
- Hospital formulary preferences.
- Availability of premixed bags during pharmacy staffing constraints.
- Temporary shortages of competing acid-suppression products.
Demand is constrained by:
- Earlier conversion to oral treatment.
- Declining use of routine stress-ulcer prophylaxis in lower-risk patients.
- Generic price competition.
- Hospital cost-containment programs.
- Substitution with famotidine or other PPIs.
- Reduced inpatient length of stay.
The premixed format may gain share within the pantoprazole category even when total pantoprazole injection volume is flat. That shift is operational rather than therapeutic.
What is the financial trajectory for pantoprazole sodium in 0.9% sodium chloride?
The product has the financial profile of a mature generic injectable:
| Financial variable | Expected direction |
|---|---|
| Unit volume | Stable to modestly declining |
| Average selling price | Downward pressure |
| Gross margin | Sensitive to manufacturing scale and contracts |
| Revenue growth | Low or negative absent shortages or new accounts |
| Competition | Persistent |
| Capital requirements | Higher than for oral solid-dose generics |
| Pricing power | Limited |
| Cash-flow quality | Dependent on contract retention and supply reliability |
Revenue can rise temporarily during supply disruptions affecting competitors. Those gains are usually not durable. Once additional suppliers restore inventory, contract prices tend to normalize.
Manufacturers with vertically integrated sterile operations may protect margins more effectively than companies dependent on third-party fill-finish providers. The most important cost variables are active pharmaceutical ingredient procurement, sterile filling, bag and port components, quality-control testing, labor, scrap, freight, and inventory carrying costs.
Why do premixed bags have a different margin profile from vials?
Premixed bags may command a higher nominal price because they reduce pharmacy preparation. They also impose higher costs:
- More complex container systems
- Larger shipping volume
- Greater packaging material usage
- Longer stability and compatibility testing
- More demanding aseptic manufacturing
- Higher risk of losses from bag defects or failed sterility batches
The economic value depends on whether hospitals recognize pharmacy labor and error-reduction benefits in purchasing decisions. Large group purchasing organizations can reduce the supplier's price premium.
What generic entry risks exist?
Generic entry risk is already realized for pantoprazole. The market is no longer exposed to a future wave of initial generic launches. The principal risk is continued price erosion from additional suppliers or aggressive contracting by established manufacturers.
For a supplier launching a new premixed product, the main risks are:
- Failure to secure hospital contracts
- Inability to achieve reliable fill rates
- FDA inspection findings
- Sterility or particulate-related recalls
- Inadequate shelf life
- Excessive manufacturing cost
- Weak distributor access
- Substitution by vial presentations
- Rapid IV-to-oral conversion
For incumbent suppliers, the greater risk is not patent invalidation. It is loss of formulary position or manufacturing reliability.
Which companies are challenging the market?
The market is challenged by manufacturers with established generic injectable portfolios and hospital distribution infrastructure. Public disclosures commonly group pantoprazole with broader injectable or generic portfolios rather than identifying product-level revenue.
Relevant company types include:
- Large multinational generic manufacturers
- U.S. hospital injectable suppliers
- Specialty sterile-injectable companies
- Contract development and manufacturing organizations
- Regional suppliers with hospital contracts
Company-specific market share should not be inferred from FDA approval listings. An approved product may have limited commercial availability, while a smaller number of suppliers may account for most actual hospital volume.
What is the Orange Book status of pantoprazole injection?
The Orange Book identifies approved prescription drug products and patent information associated with applicable listed drugs. For a mature genericized product such as pantoprazole injection, Orange Book status is mainly relevant for confirming the reference product and any listed patent claims that remain pertinent to a specific dosage form or use.[3]
The commercial conclusion is straightforward: Orange Book-listed historical patents do not create a broad current barrier to generic pantoprazole injection. Product-by-product diligence is still necessary before a launch, acquisition, or litigation assessment.
Is a Paragraph IV challenge still commercially important?
A Paragraph IV challenge is unlikely to be the central commercial event for the core pantoprazole injection market because the primary exclusivity period has ended. Paragraph IV litigation could still arise around a later formulation or delivery presentation, but the value would depend on the scope and remaining term of the specific patent.
A new entrant is more likely to compete through regulatory approval and hospital contracting than through litigation against the historical branded estate.
What patent litigation and settlement activity affect the product?
Historical Protonix patent litigation involved the branded product's earlier market protection. Those disputes were relevant during the original generic-entry period, not as a continuing barrier to current competition.
For the premixed 0.9% sodium chloride presentation, litigation risk is more likely to involve:
- A narrow formulation patent
- Container or packaging claims
- Manufacturing-process claims
- Trade-secret allegations
- Regulatory exclusivity tied to a specific presentation
- Product liability or quality claims
Settlement agreements involving the original oral or delayed-release Protonix market should not automatically be treated as applicable to current ready-to-use intravenous bags.
How strong is the patent estate for pantoprazole sodium in 0.9% sodium chloride?
The patent estate is weak for broad market exclusion and potentially moderate for narrow product-specific claims.
| Patent layer | Current strength |
|---|---|
| Pantoprazole compound | Weak or expired |
| Broad therapeutic use | Weak |
| Standard injection formulation | Limited |
| Premixed bag formulation | Potentially narrow and design-aroundable |
| Manufacturing process | Potentially relevant but difficult to enforce broadly |
| Container or delivery system | Depends on claim scope and remaining term |
| Overall exclusivity | Low |
The product's defensibility comes from manufacturing know-how, regulatory compliance, supply continuity, and customer contracts rather than from a strong patent moat.
What generic launch scenarios are most likely?
Scenario 1: Stable generic competition
This is the base case. Multiple suppliers remain active, prices decline gradually, and total demand is flat to modestly lower. Premixed bags retain a convenience premium but face vial substitution.
Scenario 2: Temporary shortage-driven pricing
A manufacturing interruption, recall, or API shortage reduces supply. Remaining suppliers gain volume and may achieve temporary price increases. The benefit fades when supply normalizes.
Scenario 3: Premixed-bag share expansion
Hospitals shift from vials to ready-to-use bags to reduce pharmacy labor and preparation steps. Total pantoprazole injection demand remains stable, but the mix shifts toward premixed products.
Scenario 4: Therapeutic substitution
Hospitals increase use of famotidine, another PPI, or oral pantoprazole. Injectable pantoprazole volume declines faster than the broader acid-suppression market.
What geographic coverage does pantoprazole have?
Pantoprazole is marketed internationally in oral and injectable forms. The United States is characterized by generic competition, hospital contracting, and substantial purchasing influence from group purchasing organizations. European and other international markets differ in reimbursement, tendering, hospital procurement, and availability of ready-to-use bags.
A product approved in one jurisdiction does not establish approval in another. The relevant commercial barriers include:
- Local marketing authorization
- Sterile manufacturing compliance
- Pharmacopoeial requirements
- Reimbursement and tender access
- Import controls
- Serialization and packaging rules
- Local distributor relationships
Geographic expansion can improve manufacturing scale, but the product remains exposed to low prices in tender-driven markets.
What manufacturing and intellectual-property barriers remain?
The principal barriers are operational rather than patent-based. A successful supplier must maintain validated sterile production, reliable component supply, strong quality systems, and enough scale to compete in hospital tenders.
Manufacturing risks include API supply interruptions, bag-film or port shortages, aseptic-processing failures, particulate contamination, failed stability batches, and capacity constraints. These risks can produce more immediate commercial disruption than patent disputes.
Key Takeaways
- Pantoprazole sodium in 0.9% sodium chloride is a mature generic injectable product.
- Core compound and branded-product exclusivity have expired.
- Biosimilar competition is irrelevant because pantoprazole is a small-molecule drug.
- Broad patent protection is weak; any remaining risk is likely to involve narrow formulation, container, or manufacturing claims.
- The market is shaped by hospital contracts, supply reliability, and IV-to-oral conversion.
- Premixed bags may command a convenience premium over vials but carry higher manufacturing and logistics costs.
- Standalone product revenue is generally not disclosed by manufacturers.
- The financial outlook is stable to declining, with temporary upside during shortages.
- Manufacturing execution and regulatory compliance are more important than patent strength.
- Generic launch economics depend on hospital access, fill rates, and cost control rather than on exclusivity.
FAQs
Is pantoprazole sodium in 0.9% sodium chloride still patent protected?
The broad pantoprazole molecule and original branded market are no longer protected by meaningful exclusivity. Narrow patents covering a particular formulation, container, or manufacturing process must be reviewed separately.
Can a generic manufacturer launch a pantoprazole premixed bag without challenging Protonix patents?
A manufacturer can generally pursue approval without challenging expired core patents. Any later-expiring patents listed for a specific presentation may require a Paragraph IV certification, Paragraph III certification, or a non-infringement strategy.
Does the premixed bag have a higher price than pantoprazole injection vials?
It can have a higher acquisition price because it reduces pharmacy preparation and handling. The premium is constrained by group purchasing contracts, hospital budgets, and competition from lower-cost vials.
Is pantoprazole injection vulnerable to drug shortages?
Yes. Sterile injectables are exposed to plant shutdowns, quality investigations, component shortages, and limited manufacturing capacity. A shortage can shift demand among pantoprazole suppliers and competing acid-suppression products.
Is pantoprazole sodium in 0.9% sodium chloride a growth product?
It is unlikely to be a high-growth product. The most plausible outlook is stable or declining underlying demand, with limited growth from premixed-format conversion, new hospital contracts, or temporary shortage-related volume.
References
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Library of Medicine. (n.d.). DailyMed: Pantoprazole sodium injection prescribing information. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
More… ↓

